PapiVax is a biotechnology company focused on immunotherapy for chronic viral infections and related cancers with Phase II assets in HPV infection and in HPV-related cancers.
PapiVax Biotech, Inc. (PBI) is a biotechnology company that intends to become a global leader in immunotherapy for chronic viral infections and related cancers…
PBI’s primary technology uses self-adjuvanting DNA vaccines administered with a heterologous booster immunization to achieve a safe and effective immunotherapeutic response.
Human papillomavirus (HPV) is the most common sexually transmitted infection and is linked to nearly all (approximately 99%) cervical cancer cases in women and 4.5% of all cancers worldwide.
PBI seeks to engage all stakeholders in our mission through presentations at many venues, and news releases on diverse media.